CRSP - CRISPRセラピュ―ティクス (CRISPR Therapeutics AG)

CRSPのニュース

   Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells ...  2021/07/21 20:38:07 GuruFocus
Related Stocks: IJH , CRSP , BA , IJR , PLTR , DFEN , DASH , ABNB , FNCL , QDEL , ISRG , TLRY , ATOM , GME , BE , ARKK , NQP , CGC ,
   Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending (MRTX, BPMC, ARNA, TBIO, SRPT, INCY, SPLK, PXD, NTNX, BRBR, SMPL, CLR, ARVN, RLAY, QURE, CRSP, ALLO, ALLK, KRTX)  2021/07/20 08:30:00 Business Insider
Summary List Placement According to data from Goldman Sachs, 2021 has been a record year for mergers and acquisitions (M&A) activity. The investment bank says M&A volume has already hit $1.9 trillion this year, marking a multi-decade high not seen since the dot-com era. The rise of special purpose acquisition companies (SPACs) in a market flush with liquidity has no doubt played a big part in the historic M&A spending figures. Goldman Sachs says 336 SPAC IPOs have raised $104 billion so far in 2021, adding to the $77 billion figure that blank-check firms raised in 2020. On top of that, the investment bank estimates there is still $118 billion of cash in 394 SPACs currently searching for an M&A target. Low interest rates, which have allowed for robust debt and equity issuance, have also pushed companies'' cash balances to record levels , meaning more M&A could be on the way. In a note to clients on Monday, Goldman analysts led by David J. Kostin predicted S&P 500 companies will spend $324 billion in cash M&A deals this year, a more-than 45% year-over-year increase.
   CRISPR Therapeutics AG Stock Is Estimated To Be Significantly Overvalued  2021/07/11 11:00:16 GuruFocus
Related Stocks: CRSP ,
   Crispr Therapeutics: Get Ready To Bail Out  2021/07/05 13:00:07 Seeking Alpha
   Crispr-Based Therapeutics Market Report 2021: Opportunities, Growth Factor, Trends, Share, Demand and Research Report Forecast to 2028 | Caribou Biosciences, Addgene, CRISPR THERAPEUTICS  2021/07/02 07:16:22 OpenPR
Crispr-Based Therapeutics Market report will provide one with overall market analysis, statistics, various trends, drivers, opportunities, restraints, and every minute data relating to the Synthetic Fibers market necessary for forecasting its revenue, factors propelling & growth. The Crispr-Based Therapeutics market
   Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer  2021/05/07 15:38:35 Benzinga
Nkarta Inc (NASDAQ: NKTX ) has collaborated with CRISPR Therapeutics AG (NASDAQ: CRSP ) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide … Full story available on Benzinga.com
   Why CRISPR Therapeutics Stock Is Trading Higher Today  2021/04/26 19:52:04 Benzinga
CRISPR Therapeutics (NASDAQ: CRSP ) shares are trading higher after … Full story available on Benzinga.com
   Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today  2021/04/26 18:18:28 Benzinga
Voyager Therapeutics, Inc. (NASDAQ: VYGR ), uniQure N.V. (NASDAQ: QURE ), Axsome Therapeutics, Inc. (NASDAQ: AXSM ), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session. Voyager Gains On Lifting of Clinical Hold On Huntington's Disease Gene Therapy: Voyager, a gene therapy company developing treatments for severe neurological diseases, said the Food and Drug Administration has removed the clinical hold imposed on the company's investigational new drug application for VY-HTT01. VY-HTT01 is a gene therapy candidate that is being evaluated for the treatment of Huntington's disease. The FDA has communicated to the company that it can proceed with the planned Phase 1/2 study. The company said it plans to initiate the study this year. Voyager was jumping 20.13% to $5.61. uniQure Says Clinical Hold On Phase 3 Hemophilia Gene Therapy Study Removed: uniQure, a gene … Full story available on Benzinga.
   CRISPR Therapeutics Is Upgraded After $900 Million Deal  2021/04/21 12:10:00 Barron's
Jefferies analyst Maury Raycroft raised his rating on the stock to Buy from Hold and lifted his target for the share price to $172 from $165.
   Crispr Gets $900M From Vertex, Tied to Gene-Editing Therapy - TheStreet  2021/04/20 15:29:33 The Street
Crispr Therapeutics rose after it said it’s receiving $900 million from Vertex Pharma, a payment tied to a gene-editing therapy.
   CRISPR Therapeutics Is Upgraded After $900 Million Deal  2021/04/21 12:10:00 Barron's
Jefferies analyst Maury Raycroft raised his rating on the stock to Buy from Hold and lifted his target for the share price to $172 from $165.
   Crispr Gets $900M From Vertex, Tied to Gene-Editing Therapy - TheStreet  2021/04/20 15:29:33 The Street
Crispr Therapeutics rose after it said it’s receiving $900 million from Vertex Pharma, a payment tied to a gene-editing therapy.
   Chardan Capital Stick to Their Buy Rating for Crispr Therapeutics AG By Investing.com  2021/04/13 12:05:09 Investing.com
Chardan Capital Stick to Their Buy Rating for Crispr Therapeutics AG
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   Meet the CRISPR pioneers who are making gene editing easy  2021/03/16 06:00:02 Fast Company
Inscripta’s Onyx—a “labtop” gene editor for the price of an SUV—could democratize an array of breakthroughs promised by CRISPR technology. Henry Ford is still best known for his 1908 Model T, an inexpensive automobile that almost anyone could own. But his real innovation was integrating the conveyor belt into assembly line production. The inspiration came from the meat packing industry. There, factory workers bled, skinned, and sliced ugly carcasses into smooth chops and filets. Ford adapted the process for cars. With the conveyor belt, he took Model T production from a 12 hour process down to roughly 90 minutes. The efficiency allowed Ford to drop the price of his Model T and led to incredible sales. It also sparked a revolution involving industrial production of all sorts. Read Full Story

calendar